Home

Moderna, Inc. - Common Stock (MRNA)

26.85
-0.64 (-2.33%)
NASDAQ · Last Trade: Oct 22nd, 7:34 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close27.49
Open27.21
Bid25.52
Ask25.70
Day's Range26.27 - 27.35
52 Week Range23.15 - 57.69
Volume7,849,065
Market Cap10.44B
PE Ratio (TTM)-3.566
EPS (TTM)-7.5
Dividend & YieldN/A (N/A)
1 Month Average Volume9,584,459

Chart

About Moderna, Inc. - Common Stock (MRNA)

Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More

News & Press Releases

Global Economic Freedom in Retreat: A Four-Year Decline Signals Looming Market Shifts
Washington D.C., October 22, 2025 – The world stands at a critical juncture as the 2025 Economic Freedom of the World index, prominently released by the Fraser Institute in collaboration with the Cato Institute, reveals an alarming and unprecedented trend: a decline in global economic freedom for four consecutive years.
Via MarketMinute · October 22, 2025
What's going on in today's after hours session: S&P500 moverschartmill.com
Discover the top S&P500 movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · October 22, 2025
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Company to discontinue development of mRNA-1647 in congenital CMV
Via ACCESS Newswire · October 22, 2025
Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.fool.com
The biotech's innovative qualities will come in handy.
Via The Motley Fool · October 22, 2025
Should You Buy Moderna Right Now?fool.com
Shares could keep sliding, as Moderna's post-COVID pipeline has yet to reach a breakthrough.
Via The Motley Fool · October 22, 2025
Wellgistics And DataVault Team Up To Transform Prescription Trackingbenzinga.com
DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.
Via Benzinga · October 22, 2025
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fallfool.com
Don't try to catch a falling surgical knife.
Via The Motley Fool · October 21, 2025
Dow Jumps More Than 500 Points Ahead Of Earnings: Investor Fear Eases, Greed Index Remains In 'Fear' Zonebenzinga.com
U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close higher, with Fear & Greed Index at 30.3.
Via Benzinga · October 21, 2025
Small Caps Rally As Credit Fears Ease, Gold Rebounds To $4,350: What's Moving Markets Monday?benzinga.com
Via Benzinga · October 20, 2025
What's going on in today's session: S&P500 moverschartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
Via Chartmill · October 20, 2025
Stay informed with the top movers within the S&P500 index on Monday.chartmill.com
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · October 20, 2025
Stock Market Today: S&P 500, Nasdaq, Dow Jones Futures Rise— Micron, Bitmine, Coinbase In Focusbenzinga.com
U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher.
Via Benzinga · October 20, 2025
2 Mid-Cap Stocks to Consider Right Now and 1 That Underwhelm
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Via StockStory · October 20, 2025
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened interest is not merely an isolated phenomenon but rather a potent indicator of broader market movements, significantly impacting stock futures and the
Via MarketMinute · October 19, 2025
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows:
Via ACCESS Newswire · October 19, 2025
Healthcare’s AI Revolution: Generative Intelligence Delivers Real Returns as Agentic Systems Drive Measurable Outcomes
The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements in generative AI are now yielding tangible benefits, delivering measurable returns across clinical and administrative domains. This shift is further amplified by the emerging paradigm of 'agentic AI,' which promises [...]
Via TokenRing AI · October 17, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Via Chartmill · October 17, 2025
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
CAMBRIDGE, MA, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 financial results, and provide a corporate update.
Via ACCESS Newswire · October 16, 2025
Why Moderna Might Be a One-Hit Wonderfool.com
Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.
Via The Motley Fool · October 15, 2025
Which S&P500 stocks are moving on Wednesday?chartmill.com
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · October 15, 2025
Wednesday's session: top gainers and losers in the S&P500 indexchartmill.com
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · October 15, 2025
Government Shutdown Casts Long Shadow Over Economy and Interest Rate Outlook Ahead of Powell's Pivotal Speech
The United States government is currently in the throes of its third week of a shutdown, a fiscal impasse that commenced on October 1, 2025, following a congressional failure to enact appropriations legislation for the 2026 fiscal year. This eleventh government shutdown in U.S. history is sending ripples of
Via MarketMinute · October 14, 2025
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potentialbenzinga.com
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.
Via Benzinga · October 14, 2025
David Gardner: 9 Foolish Truths I Hold to Be Self-Evidentfool.com
Whether you're well steeped in Foolishness or at the beginning stages of your investing journey, these are nine foundational truths not to be forgotten.
Via The Motley Fool · October 14, 2025
Moderna (MRNA) Stock Trades Up, Here Is Why
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped in the afternoon session after the company presented promising early data for its investigational cancer antigen therapy, mRNA-4359, from a Phase I/II study. 
Via StockStory · October 13, 2025